IminoTech today announced results from a new randomised, double-blind, placebo-controlled clinical trial showing that Q-actin (cucumber extract standardised to idoBR1) at 20 mg/day significantly improved joint comfort and function in adults with mild-to-moderate joint pain during 60 days.
The study, published in Cureus, adds to a growing body of evidence for Q-actin’s efficacy at a remarkably small daily serving.
Eighty adults with mild-to-moderate joint pain consumed 20 mg/day of Q-actin or placebo for 60 days.
Assessments were conducted at days 15, 30 and 60 using WOMAC, Lequesne Functional Index, Brief Pain Inventory (BPI) and Pain Disability Index (PDI).
Significant improvements with Q-actin emerged by day 30 and strengthened throughout the study.
By day 60, Q-actin participants experienced a 31.79% decrease in WOMAC scores (less pain and stiffness and better function), a 32.39% reduction on the PDI (less interference with work, sleep, mood and daily activities) and a 10.07% improvement on the Lequesne Functional Index (measurable gains in mobility and functional capacity).
Per cent changes are within-group from baseline to day 60.
“These results not only confirm Q-actin’s benefits, they extend them beyond previous osteoarthritis studies to adults with mild to moderate joint pain,” said Shil Kothari, Chief Executive Officer of IminoTech.
“Consistent outcomes with a tiny 20 mg daily dose show Q-actin delivers reliable, everyday joint health benefits that consumers can feel.”